S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
My No. 1 dividend stock for a LIFETIME of income. (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
My No. 1 dividend stock for a LIFETIME of income. (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
My No. 1 dividend stock for a LIFETIME of income. (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
My No. 1 dividend stock for a LIFETIME of income. (Ad)
First Republic Bank Hits New Low, Dimon Pushes for More Cash
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
General Mills Retreats To Buy Zone Ahead Of Earnings 
CVE:AQS

Aequus Pharmaceuticals - AQS Stock Forecast, Price & News

C$0.03
-0.01 (-25.00%)
(As of 03/16/2023)
Add
Compare
Today's Range
C$0.03
C$0.03
50-Day Range
C$0.03
C$0.05
52-Week Range
C$0.02
C$0.10
Volume
10,000 shs
Average Volume
155,214 shs
Market Capitalization
C$3.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AQS stock logo

About Aequus Pharmaceuticals (CVE:AQS) Stock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Stock News Headlines

Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Aequus Reports Third Quarter 2022 Financial Highlights
Aequus Pharmaceuticals Inc
Aequus Pharmaceuticals reports Q2 results
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
IIROC Trading Resumption - AQS
Aequus Resumes Trading on TSX Venture Exchange
IIROC Trading Halt - AQS.WT
IIROC Trading Halt - AQS.DB
Aequus Announces Director Resignation
Aequus Provides Commercial Update
Aequus Provides update on Warrant Acceleration
See More Headlines
Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Company Calendar

Today
3/20/2023
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Net Income
C$-2,520,000.00
Net Margins
-135.60%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.86 million
Cash Flow
C$0.01 per share

Miscellaneous

Free Float
N/A
Market Cap
C$3.98 million
Optionable
Not Optionable
Beta
0.49

Key Executives

  • Mr. Douglas Glen Janzen (Age 54)
    Chairman, CEO & Pres
    Comp: $225k
  • Ms. Ann Fehr CGA (Age 54)
    CPA, CFO & Corp. Sec.
    Comp: $155.94k
  • Mr. Stuart Fowler
    Strategic Commercial Advisor & Independent Director
  • Mr. Grant Larsen
    Chief Commercial Officer













AQS Stock - Frequently Asked Questions

How have AQS shares performed in 2023?

Aequus Pharmaceuticals' stock was trading at C$0.04 at the beginning of 2023. Since then, AQS stock has decreased by 14.3% and is now trading at C$0.03.
View the best growth stocks for 2023 here
.

When is Aequus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our AQS earnings forecast
.

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF).

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.03.

How much money does Aequus Pharmaceuticals make?

Aequus Pharmaceuticals (CVE:AQS) has a market capitalization of C$3.98 million and generates C$1.86 million in revenue each year. The company earns C$-2,520,000.00 in net income (profit) each year or C($0.01) on an earnings per share basis.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The official website for the company is www.aequuspharma.ca. The company can be reached via phone at +1-604-3367906.

This page (CVE:AQS) was last updated on 3/21/2023 by MarketBeat.com Staff